|1.||Fujii, Yoshitaka: 15 articles (12/2011 - 01/2002)|
|2.||Tanaka, Hiroyoshi: 8 articles (01/2005 - 01/2002)|
|3.||Do, Sang-Hwan: 5 articles (09/2015 - 04/2010)|
|4.||Hirata, Takuya: 5 articles (05/2014 - 07/2007)|
|5.||Keto, Yoshihiro: 5 articles (05/2014 - 07/2007)|
|6.||Kwak, Young Lan: 4 articles (04/2014 - 08/2008)|
|7.||Ryu, Jung-Hee: 4 articles (01/2014 - 09/2011)|
|8.||Akuzawa, Shinobu: 4 articles (05/2009 - 07/2007)|
|9.||Funatsu, Toshiyuki: 4 articles (05/2009 - 07/2007)|
|10.||Sasamata, Masao: 4 articles (05/2009 - 07/2007)|
|1.||Postoperative Nausea and Vomiting (PONV)
11/01/2011 - "Compared with placebo, the efficacy of 0.3 mg ramosetron in adults and 6 µg/kg in children were consistently beneficial in preventing PONV overall (RR: 0.4; 95% CI: 03-0.6). "
04/01/2011 - "Prophylactic therapy with ramosetron is effective for preventing PONV in adults and POV in children without clinically serious adverse effects."
09/01/2008 - "Ramosetron is effective for the long-term (up to 48 h) prevention of PONV. "
01/01/2006 - "Ramosetron is effective for the long-term (up to 48 hours) prevention of PONV. "
01/01/2005 - "Ramosetron is effective for the long-term prevention of PONV. "
01/01/2015 - "This study shows a trend regarding the dose-response relationship for ramosetron to prevent CINV, including delayed emesis. "
12/01/2003 - "The number of emesis-free patients in the ramosetron 0.15-mg group and the placebo group were similar after both study periods. "
08/20/2005 - "The control rate of vomiting by ramosetron was 88%, 86% and 90% for the first three days. "
02/01/2004 - "Overall in 24 h, patients receiving oral ramosetron experienced no emesis slightly higher than that of the i.v. group (55% and 36% respectively, p = 0.05). "
01/01/2004 - "If vomiting occurred in the following 24 h, patients in both groups received an intravenous rescue dose of ramosetron 300 microg. "
06/01/2012 - "The ramosetron group tended to have a lower incidence of nausea with a higher complete response and tended to have less severe nausea and fewer rescue antiemetic requirements during the 6- to 24-hour period. "
08/01/2011 - "During the first 6 h, the severity of nausea and the use of rescue antiemetic medication were significantly lower in the ramosetron group. "
05/01/2010 - "The incidence of nausea between 2 and 24 h and the severity of nausea between 2 and 48 h were also less in the ramosetron group. "
08/20/2005 - "The effective rate of nausea by ramosetron was 82%, 72% and 84% for the first three days. "
10/01/2012 - "Ramosetron was also more effective in studies by Fujii et al.: vomiting 0.60 (0.39-0.91), p=0.02; nausea or vomiting 0.71 (0.56-0.91); p=0.006. "
07/01/2014 - "Thus, our results suggest that ramosetron can be administered safely, without gastrointestinal adverse effects, even to terminal cancer patients with delayed or accelerated gastric emptying abnormality."
06/01/1996 - "There was no evidence of a treatment-related effect on the incidence of any tumor or tumor type, and there were no non-neoplastic findings considered to be related to the administration of YM060. "
11/01/2012 - "Patients received palonosetron followed by ramosetron, and the antiemetic effects were evaluated by the Multinational Association of Supportive Care in Cancer Antiemesis Tool(MAT). "
12/01/2005 - "Thirty in-patients with malignant tumor being treated with cisplatin at a dose of 70 mg/m2 or more for a total of 94 cycles were scheduled to receive ramosetron 0. "
02/01/2009 - "Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer."
06/01/2014 - "We performed a randomized, double-blind, placebo-controlled trial to determine whether ramosetron reduces diarrhea in these patients. "
01/01/2013 - "In a double-blind, placebo-controlled, parallel-group study of 418 patients with diarrhea-predominant IBS-D, once-daily 5 μg and 10 μg doses of ramosetron increased the monthly responder rates of IBS symptoms compared to placebo. "
05/01/2014 - "Ramosetron is under evaluation for diarrhea-predominant IBS due to its acceptable safety and tolerability, besides its efficacy. "
04/01/2013 - "Is Ramosetron Really Useful to Treat Diabetic Diarrhea With Rapid Small Bowel Transit?: Author's Reply."
04/01/2013 - "Is ramosetron really useful to treat diabetic diarrhea with rapid small bowel transit?"
|5.||Serotonin (5 Hydroxytryptamine)
|1.||Drug Therapy (Chemotherapy)
|4.||Patient-Controlled Analgesia (Analgesia, Patient Controlled)
|5.||Gynecologic Surgical Procedures (Gynecologic Surgery)